Recently, sulfobutyl ether cyclodextrin (SBECD) has drawn extensive attention in the medical field. As a sulfonic acid derivative of β-cyclodextrin, it has become a "key to solving the absorption problem of poorly soluble drugs" due to its unique molecular structure and supramolecular chemical properties.
Technical Breakthrough: From Laboratory to Clinic
SBECD introduces sulfobutyl ether chains to the hydroxyl groups at positions 2, 3, and 6 of β-cyclodextrin, forming an anionic, highly water-soluble derivative. Its molecular cavity can precisely encapsulate hydrophobic drug molecules, forming stable non-covalent complexes, significantly enhancing drug solubility and stability. For instance, Pfizer's injectable ziprasidone, with the aid of SBECD technology, has increased its solubility several times, making the previously difficult-to-inject formulation possible. By 2025, 12 SBECD-based injectables have been approved globally, covering antifungal drugs (posaconazole), antiviral drugs (remdesivir), and antitumor drugs (carfilzomib), among others.
Clinical Value: Dual Upgrade in Safety and Efficacy
Compared to traditional cyclodextrins, SBECD has lower nephrotoxicity and weaker hemolytic properties. Studies show that it can prolong drug half-life and increase bioavailability by inhibiting P-glycoprotein efflux. For example, in the case of the tolfenpyrad inclusion complex, SBECD increased the peak blood drug concentration by 40% and prolonged the half-life by 2 hours. Additionally, SBECD can mask the unpleasant odor of drugs and reduce injection site irritation, providing a more pleasant experience for patients.
Industrial Prospect: The Rise of the Chinese Market
Currently, five SBECD solubilized drugs, including voriconazole and ziprasidone, have been launched in China, and many enterprises are accelerating their layout. Experts point out that with the growth of personalized medicine and the demand for high-end formulations, SBECD has huge application potential in sustained-release and controlled-release formulations and targeted drug delivery systems, and may become a "booster" for the upgrading of the pharmaceutical industry.
From laboratory innovation to clinical application, sulfobutyl ether cyclodextrin is reshaping the future landscape of pharmaceutical formulations with the posture of a "hidden champion".
